Intra-Cellular Therapies Inc
Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company that develops and commercializes therapeutics and small molecule drugs for central nervous system (CNS), neuropsychiatric, and neurological disorders. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It distributes its products through third-party wholesale drug distributors. The … Read more
Intra-Cellular Therapies Inc (ITCI) - Total Liabilities
Latest total liabilities as of December 2024: $218.45 Million USD
Based on the latest financial reports, Intra-Cellular Therapies Inc (ITCI) has total liabilities worth $218.45 Million USD as of December 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Intra-Cellular Therapies Inc - Total Liabilities Trend (2011–2024)
This chart illustrates how Intra-Cellular Therapies Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Intra-Cellular Therapies Inc Competitors by Total Liabilities
The table below lists competitors of Intra-Cellular Therapies Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Repsol S.A
OTCQX:REPYF
|
USA | $32.71 Billion |
|
Wal-Mart de México S.A.B. de C.V
MX:WALMEX
|
Mexico | MX$263.41 Billion |
|
Dawning Information Industry Co Ltd
SHG:603019
|
China | CN¥15.04 Billion |
|
Fortescue Metals Group Ltd
OTCQX:FSUMF
|
USA | $10.56 Billion |
|
Repsol SA
OTCQX:REPYY
|
USA | $32.71 Billion |
|
Coca-Cola Consolidated Inc.
NASDAQ:COKE
|
USA | $5.36 Billion |
|
ANTA Sports Products Ltd
PINK:ANPDF
|
USA | $48.51 Billion |
|
Kasikornbank Public Co Ltd
PINK:KPCPY
|
USA | $3.89 Trillion |
Liability Composition Analysis (2011–2024)
This chart breaks down Intra-Cellular Therapies Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.36 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Intra-Cellular Therapies Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Intra-Cellular Therapies Inc (2011–2024)
The table below shows the annual total liabilities of Intra-Cellular Therapies Inc from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $218.45 Million | +59.60% |
| 2023-12-31 | $136.87 Million | +38.66% |
| 2022-12-31 | $98.71 Million | +37.04% |
| 2021-12-31 | $72.03 Million | +19.15% |
| 2020-12-31 | $60.45 Million | +7.61% |
| 2019-12-31 | $56.18 Million | +42.26% |
| 2018-12-31 | $39.49 Million | +131.63% |
| 2017-12-31 | $17.05 Million | +27.23% |
| 2016-12-31 | $13.40 Million | +70.48% |
| 2015-12-31 | $7.86 Million | -25.54% |
| 2014-12-31 | $10.56 Million | +54.48% |
| 2013-12-31 | $6.83 Million | +140.67% |
| 2012-12-31 | $2.84 Million | -50.21% |
| 2011-12-31 | $5.70 Million | -- |